Avoiding tolerance against prostatic antigens with subdominant peptide epitopes

Michael E. Grossmann, Eduardo Davila, Esteban Celis

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

A potential novel therapy for prostate cancer is the induction of immune responses to normal prostate-associated antigens (PAA). One approach is to use synthetic peptides from PAA to educate T cells as a means of developing a defined and specific immunotherapy for prostate cancer. A likely major hurdle when using normal PAA for this type of therapy is the tolerance that the immune system may already have for PAA. To evaluate mechanisms for overcoming tolerance, the authors assessed the level of tolerance to SV40T antigen in a transgenic mouse. The SV40T antigen is selectively expressed in the prostates of mice from the transgenic adenocarcinoma mouse prostate (TRAMP) model. The authors have shown that TRAMP mice are tolerant to a dominant cytotoxic T-lymphocyte (CTL) epitope from the SV40T antigen compared with nontransgenic littermates. The tolerance was exhibited as early as 4 weeks and as late as 24 weeks. The use of multiple injections of an oligonucleotide that contains an unmethylated CpG induced high levels of hematopoiesis but did not overcome the tolerance. Injection of an antibody to activate CD40 increased the CTL response in normal mice but also did not overcome tolerance. However, tolerance in the TRAMP mice was avoided when an epitope that had previously been characterized as a subdominant epitope was administered. The authors are investigating the potential of subdominant epitopes to induce prostatitis and antitumor responses. The results of this work should facilitate the development of immune-based therapies for prostate cancer.

Original languageEnglish (US)
Pages (from-to)237-241
Number of pages5
JournalJournal of Immunotherapy
Volume24
Issue number3
DOIs
StatePublished - Jun 7 2001
Externally publishedYes

Fingerprint

Prostate
Epitopes
Antigens
Peptides
Transgenic Mice
Prostatic Neoplasms
Adenocarcinoma
Cytotoxic T-Lymphocytes
Prostatitis
Injections
T-Lymphocyte Epitopes
Hematopoiesis
Oligonucleotides
Immunotherapy
Immune System
Therapeutics
T-Lymphocytes
Antibodies

Keywords

  • Immunotherapy
  • Prostate cancer
  • SV40T
  • T lymphocytes
  • Tumor model

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. / Grossmann, Michael E.; Davila, Eduardo; Celis, Esteban.

In: Journal of Immunotherapy, Vol. 24, No. 3, 07.06.2001, p. 237-241.

Research output: Contribution to journalArticle

Grossmann, Michael E. ; Davila, Eduardo ; Celis, Esteban. / Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. In: Journal of Immunotherapy. 2001 ; Vol. 24, No. 3. pp. 237-241.
@article{9f6fea7fa58444ceb930540e65478311,
title = "Avoiding tolerance against prostatic antigens with subdominant peptide epitopes",
abstract = "A potential novel therapy for prostate cancer is the induction of immune responses to normal prostate-associated antigens (PAA). One approach is to use synthetic peptides from PAA to educate T cells as a means of developing a defined and specific immunotherapy for prostate cancer. A likely major hurdle when using normal PAA for this type of therapy is the tolerance that the immune system may already have for PAA. To evaluate mechanisms for overcoming tolerance, the authors assessed the level of tolerance to SV40T antigen in a transgenic mouse. The SV40T antigen is selectively expressed in the prostates of mice from the transgenic adenocarcinoma mouse prostate (TRAMP) model. The authors have shown that TRAMP mice are tolerant to a dominant cytotoxic T-lymphocyte (CTL) epitope from the SV40T antigen compared with nontransgenic littermates. The tolerance was exhibited as early as 4 weeks and as late as 24 weeks. The use of multiple injections of an oligonucleotide that contains an unmethylated CpG induced high levels of hematopoiesis but did not overcome the tolerance. Injection of an antibody to activate CD40 increased the CTL response in normal mice but also did not overcome tolerance. However, tolerance in the TRAMP mice was avoided when an epitope that had previously been characterized as a subdominant epitope was administered. The authors are investigating the potential of subdominant epitopes to induce prostatitis and antitumor responses. The results of this work should facilitate the development of immune-based therapies for prostate cancer.",
keywords = "Immunotherapy, Prostate cancer, SV40T, T lymphocytes, Tumor model",
author = "Grossmann, {Michael E.} and Eduardo Davila and Esteban Celis",
year = "2001",
month = "6",
day = "7",
doi = "10.1097/00002371-200105000-00007",
language = "English (US)",
volume = "24",
pages = "237--241",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Avoiding tolerance against prostatic antigens with subdominant peptide epitopes

AU - Grossmann, Michael E.

AU - Davila, Eduardo

AU - Celis, Esteban

PY - 2001/6/7

Y1 - 2001/6/7

N2 - A potential novel therapy for prostate cancer is the induction of immune responses to normal prostate-associated antigens (PAA). One approach is to use synthetic peptides from PAA to educate T cells as a means of developing a defined and specific immunotherapy for prostate cancer. A likely major hurdle when using normal PAA for this type of therapy is the tolerance that the immune system may already have for PAA. To evaluate mechanisms for overcoming tolerance, the authors assessed the level of tolerance to SV40T antigen in a transgenic mouse. The SV40T antigen is selectively expressed in the prostates of mice from the transgenic adenocarcinoma mouse prostate (TRAMP) model. The authors have shown that TRAMP mice are tolerant to a dominant cytotoxic T-lymphocyte (CTL) epitope from the SV40T antigen compared with nontransgenic littermates. The tolerance was exhibited as early as 4 weeks and as late as 24 weeks. The use of multiple injections of an oligonucleotide that contains an unmethylated CpG induced high levels of hematopoiesis but did not overcome the tolerance. Injection of an antibody to activate CD40 increased the CTL response in normal mice but also did not overcome tolerance. However, tolerance in the TRAMP mice was avoided when an epitope that had previously been characterized as a subdominant epitope was administered. The authors are investigating the potential of subdominant epitopes to induce prostatitis and antitumor responses. The results of this work should facilitate the development of immune-based therapies for prostate cancer.

AB - A potential novel therapy for prostate cancer is the induction of immune responses to normal prostate-associated antigens (PAA). One approach is to use synthetic peptides from PAA to educate T cells as a means of developing a defined and specific immunotherapy for prostate cancer. A likely major hurdle when using normal PAA for this type of therapy is the tolerance that the immune system may already have for PAA. To evaluate mechanisms for overcoming tolerance, the authors assessed the level of tolerance to SV40T antigen in a transgenic mouse. The SV40T antigen is selectively expressed in the prostates of mice from the transgenic adenocarcinoma mouse prostate (TRAMP) model. The authors have shown that TRAMP mice are tolerant to a dominant cytotoxic T-lymphocyte (CTL) epitope from the SV40T antigen compared with nontransgenic littermates. The tolerance was exhibited as early as 4 weeks and as late as 24 weeks. The use of multiple injections of an oligonucleotide that contains an unmethylated CpG induced high levels of hematopoiesis but did not overcome the tolerance. Injection of an antibody to activate CD40 increased the CTL response in normal mice but also did not overcome tolerance. However, tolerance in the TRAMP mice was avoided when an epitope that had previously been characterized as a subdominant epitope was administered. The authors are investigating the potential of subdominant epitopes to induce prostatitis and antitumor responses. The results of this work should facilitate the development of immune-based therapies for prostate cancer.

KW - Immunotherapy

KW - Prostate cancer

KW - SV40T

KW - T lymphocytes

KW - Tumor model

UR - http://www.scopus.com/inward/record.url?scp=0034996564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034996564&partnerID=8YFLogxK

U2 - 10.1097/00002371-200105000-00007

DO - 10.1097/00002371-200105000-00007

M3 - Article

VL - 24

SP - 237

EP - 241

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 3

ER -